Categories
Colon Cancer

Adding chemotherapy to immunotherapy in metastatic CRC [Video]

Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, presents data from the phase Ib KEYNOTE-651 trial (NCT03374254), which assessed pembrolizumab with modified FOLFOX7 or FOLFIRI in patients with metastatic colorectal cancer (mCRC). In two out of five cohorts, patients with microsatellite stable CRC were given first- or second-line pembrolizumab with modified FOLFOX7 or FOLFIRI and the progression-free survival (PFS) was found to be comparable to that of patients not receiving pembrolizumab. Dr Kim additionally discusses the efficacy of certain biomarkers such as PD-L1 levels and the mutational status of KRAS in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

RNA profiling of circulating tumor cells in myeloma patients [Video]

Elizabeth D. Lightbody, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the value of investigating circulating tumor cells (CTCs) in patients with multiple myeloma. CTCs are present at all stages of the myeloma disease continuum, and CTC levels increase with disease progression. Dr Lightbody discusses some research in which single-cell RNA sequencing was performed on a subset of patients and healthy donors to analyze CTC profiles, and the value of using CTCs as a biomarker of disease. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Categories
Colon Cancer

Safety and efficacy of cytokine-induced killer cells for colorectal cancer treatment [Video]

Fayyaz, et al. “Cytokine-Induced Killer Cells Mediated Pathways in the Treatment of Colorectal Cancer.” Cell Communication and Signaling (2022)Read the article: https://doi.org/10.1186/s12964-022-00836-0Video produced by http://www.researchsquare.com/researchers/videos

Categories
Blood Cancer

Long-term follow-up results of TOURMALINE-MM2: IRd vs pbo-Rd in multiple myeloma [Video]

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an update on the long-term results of the TOURMALINE-MM2 trial comparing ixazomib-lenalidomide-dexamethasone (IRd) to placebo-lenalidomide-dexamethasone (pbo-Rd) in patients with relapsed/refractory (R/R) multiple myeloma (NCT01850524). The results of this study showing a significantly improved progression-free survival (PFS) in patients treated with IRd led to the approval of ixazomib in the relapsed/refractory (R/R) setting. Long-term subgroup analysis revealed that an improved quality of response over time was correlated with better patient outcomes and suggests that treatment with ixazomib should be prolonged over an extended period of time to maximize benefits. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

GRIFFIN: subgroup analysis of patients with multiple myeloma with high-risk cytogenetics [Video]

Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, outlines the results of a subgroup analysis of the GRIFFIN trial (NCT02874742) investigating the efficacy of the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (D-RVd) in patients with multiple myeloma with high-risk cytogenetics. Dr Voorhees explains that adding 1q21 gain to the high-risk markers defined by IMWG criteria increases the study’s power which allows determining whether daratumumab provides a significant benefit to this patient population. After incorporating patients with 1q21 gain to the subgroup analysis, the study reported a trend towards an improved progression-free survival (PFS) for high-risk patients treated with D-RVd compared to RVd alone. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

GLOW: Assessing ibrutinib plus venetoclax in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses findings in the Phase III GLOW trial (NCT03462719), which assessed first-line ibrutinib plus venetoclax versus chlorambucil with obinutuzumab in patients with chronic lymphocytic leukemia (CLL). Patients receiving ibrutinib and venetoclax reported lower rates of relapse, and Dr Niemann suggests intermediate minimal residual disease (MRD) as an acceptable endpoint for certain patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Treating Richter’s transformation with venetoclax, obinutuzumab and atezolizumab [Video]

Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the Phase II trial (NCT02846623) of venetoclax, obinutuzumab and atezolizumab in patients with Richter’s transformation, an aggressive form of chronic lymphocytic leukemia (CLL) that is currently an area of unmet medical need. A total of 7 patients are currently enrolled and all patients achieved remission after treatment, with 3 patients proceeding to undergo allogeneic stem cell transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

GAIA/CLL13: Venetoclax-based time-limited combination therapies in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, gives an overview of the Phase III GAIA trial (NCT02950051), which assessed standard chemoimmunotherapy versus a combination of rituximab, venetoclax, obinutuzumab, and ibrutinib in patients with chronic lymphocytic leukemia (CLL). Patients received either standard chemoimmunotherapy, rituximab with venetoclax, obinutuzumab with venetoclax, or obinutuzumab with ibrutinib and venetoclax. Rituximab or obinutuzumab with venetoclax were associated with higher rates of undetectable minimal residual disease (uMRD), and whilst addition of ibrutinib added further benefit to patients, more adverse events were reported. Further research is required to identify patient subgroups who will benefit from chemoimmunotherapy the most. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

HOVON 141/VISION: MRD guided time-limited treatment in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, presents results from the prospective, randomized Phase II HOVON-141/VISION trial (NCT03226301), which assessed time-limited venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Patients reaching undetectable minimal residual disease (MRD) after venetoclax and ibrutinib either received maintenance ibrutinib or stopped treatment, and all patients who failed to reach MRD status received maintenance ibrutinib. MRD guided time-limited treatment was proven to be beneficial, where the primary endpoint of progression-free survival (PFS) was met. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Meta-analysis of cilta-cel in patients with R/R multiple myeloma [Video]

Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, is currently being investigated in patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial (NCT03548207). Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, provides an overview of findings from a meta-analysis of cilta-cel verus the standard of care. Data from various real world registries and clinical trials such as POLLUX (NCT02076009) and CASTOR (NCT02136134), were analyzed and patients receiving cilta-cel had superior progression-free survival and overall survival. Despite cilta-cel causing more adverse events, patients overall reported a better quality of life. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Atezolizumab with venetoclax and obinutuzumab in patients with CLL [Video]

Whilst atezolizumab, a PD-L1 checkpoint inhibitor, has only been approved in solid tumor indications, studies have suggested checkpoint inhibitors with venetoclax may have clinical benefit in patients with chronic lymphocytic leukemia (CLL). Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, presents findings from a Phase II trial (NCT02846623) of venetoclax, obinutuzumab, and atezolizumab in patients with chronic lymphocytic leukemia. The regimen resulted in high rated of remission in bone marrow and had an acceptable safety profile. Whilst no patients have currently progressed, more follow up is required to accurately determine progression-free survival (PFS). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

ELARA: Tisa-cel in follicular lymphoma [Video]

Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an update on the Phase II ELARA trial (NCT03568461), which assessed tisagenlecleucel (tisa-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with follicular lymphoma (FL). Tisa-cel improved progression-free survival across different subtypes of FL, including patients who progressed within 2 years (POD24). Patients who received tisa-cel in an outpatient setting also were less likely to require hospitalization, highlighting the ability for CAR T-cell therapies to be administered in an outpatient setting for patients with a low-risk disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.